Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 23, 2017Current Vascular Pharmacology

Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target

View Full Paper
Ask AI
Bookmark
Share

Key result

VWF inhibitors demonstrate promising antithrombotic properties in preliminary studies.

Why the study?

There is an unmet need in antithrombotic therapy requiring new complementary strategies targeting von Willebrand Factor to counteract thrombus formation and propagation.

Design

Review

Authors

FGFelice GragnanoEGEnrica GoliaFNFrancesco Natale

Discussion

Loading...

Member takes

Overview

VWF inhibition shows preclinical promise; leaves open translation to human antithrombotic therapy.

Structured PICO

I
Intervention
Von Willebrand Factor (VWF) antagonists, including monoclonal antibodies, aptamers, nanobodies, and unselective antagonists (LMWHs, statins, N-acetylcysteine, glycoprotein IIb/IIIa inhibitors)

Von Willebrand Factor represents a promising therapeutic target for novel antithrombotic strategies to counteract thrombus formation and propagation.

Cite This Study

Gragnano et al. (2017) conducted a review in Cardiovascular Disease. Von Willebrand Factor (VWF) inhibitors was evaluated. Von Willebrand Factor is a pivotal contributor to clot formation and an emerging therapeutic target, with several tailor-made inhibitors demonstrating antithrombotic properties in preliminary studies.

synapsesocial.com/papers/6aaa2b915e1c2e91a8fbd01chttps://doi.org/10.2174/1570161115666170201114835
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders.2025
  2. 2Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease2013 · 25 citations
  3. 3Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target2013 · 14 citations
  4. 4Role of von Willebrand factor in vascular disease2009 · 56 citations
  5. 5Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence2018 · 46 citations